Wayne Godfrey, M.D.

Chief Medical Officer

Prior to joining Janux, Wayne served as the Vice President of Clinical Development of IGM Biosciences, Inc., where he led the global clinical development of IGM’s emerging pipeline of proprietary bispecific T-cell engaging IgM antibodies. Prior to IGM, he served as Senior Director, Clinical Development at Kite Pharma, a biotechnology company and subsidiary of Gilead Sciences, where he led the CAR-T CD19-directed pivotal Phase 2 study, ZUMA-5. Wayne also served as Chief Medical Officer at Etubics, and Senior Director, Clinical Research Oncology at Gilead where he advanced ZYDELIG^® (idelalisib) through late-stage development, leading the design of global Phase 3 trials, and helping to obtain accelerated approval for its use for follicular lymphoma. Prior to Gilead, he worked as Vice President of Clinical Development at Bavaian-Nordic on Prostate and Breast cancer vaccines, and he helped develop PROVENGE^® (sipuleucel-T) at Dendreon.

Wayne earned a B.A. in biochemistry and molecular biology from UC Santa Barbara, an M.S. in biology from Stanford University, and an M.D. from Washington University School of Medicine in St. Louis. Wayne completed his internal medicine residency and fellowships in clinical immunology, hematology, and bone marrow transplantation at Stanford University.